Glycaemic and cardiovascular efficacy of liraglutide in prediabetic patients with end-stage renal disease

Trial Profile

Glycaemic and cardiovascular efficacy of liraglutide in prediabetic patients with end-stage renal disease

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 07 Sep 2015

At a glance

  • Drugs Liraglutide (Primary)
  • Indications Prediabetic-state; Renal failure
  • Focus Therapeutic Use
  • Acronyms The LiRA2 study
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 21 Aug 2015 Status changed from recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
    • 04 May 2015 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top